(-0.18%) 5 459.71 points
(-0.14%) 39 059 points
(0.08%) 17 732 points
(-0.20%) $80.67
(-3.70%) $2.65
(-0.71%) $2 314.20
(0.13%) $28.91
(1.97%) $1 005.80
(0.30%) $0.936
(0.77%) $10.69
(0.49%) $0.792
(0.00%) $87.49
Live Chart Being Loaded With Signals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide...
Stats | |
---|---|
आज की मात्रा | 14 790 |
औसत मात्रा | 143 814 |
बाजार मूल्य | 1.40B |
EPS | $4.86 ( Q1 | 2024-05-08 ) |
अगली कमाई की तारीख | ( $0 ) 2024-08-06 |
Last Dividend | $0.456 ( 2010-07-02 ) |
Next Dividend | $0 ( N/A ) |
P/E |
14.56 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.111 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-14 | Sabba Stephen L | Buy | 1 252 | Common Stock |
2024-06-14 | Sabba Stephen L | Buy | 5 444 | Non-Qualified Stock Option (right to buy) |
2024-06-14 | Zimmermann Martine | Buy | 5 444 | Non-Qualified Stock Option (right to buy) |
2024-06-14 | Zimmermann Martine | Buy | 1 252 | Common Stock |
2024-06-14 | Lamattina John L | Buy | 1 252 | Common Stock |
INSIDER POWER |
---|
56.10 |
Last 99 transactions |
Buy: 467 765 | Sell: 133 743 |
मात्रा सहसंबंध
Ligand Pharmaceuticals सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध |
---|
10 सबसे अधिक नकारात्मक सहसंबंध |
---|
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Ligand Pharmaceuticals सहसंबंध - मुद्रा/वस्त्र
Ligand Pharmaceuticals वित्तीय
Annual | 2023 |
राजस्व: | $131.31M |
सकल लाभ: | $119.75M (91.20 %) |
EPS: | $3.02 |
FY | 2023 |
राजस्व: | $131.31M |
सकल लाभ: | $119.75M (91.20 %) |
EPS: | $3.02 |
FY | 2022 |
राजस्व: | $196.25M |
सकल लाभ: | $143.42M (73.08 %) |
EPS: | $-0.310 |
FY | 2021 |
राजस्व: | $277.13M |
सकल लाभ: | $214.96M (77.56 %) |
EPS: | $2.22 |
Financial Reports:
No articles found.
Ligand Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $9.36 | 2007-04-03 |
Last Dividend | $0.456 | 2010-07-02 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $9.81 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.24 | -- |
Div. Sustainability Score | 9.60 | |
Div.Growth Potential Score | 3.88 | |
Div. Directional Score | 6.74 | -- |
Year | Amount | Yield |
---|---|---|
2007 | $9.36 | 14.30% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0.456 | 3.50% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
02 Jul 2010 | $0.456 | 30 Nov -0001 | 28 Jun 2010 | 30 Nov -0001 |
03 Apr 2007 | $9.36 | 22 Mar 2007 | 05 Apr 2007 | 19 Apr 2007 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.793 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.103 | 1.200 | 6.58 | 7.89 | [0 - 0.3] |
returnOnEquityTTM | 0.132 | 1.500 | 9.64 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 20.70 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 19.03 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.81 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00678 | -1.500 | 9.89 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -1.073 | 1.000 | -1.508 | -1.508 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.935 | 2.00 | 9.35 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -0.971 | 2.00 | -0.486 | -0.971 | [0 - 20] |
debtEquityRatioTTM | 0.00768 | -1.500 | 9.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.849 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.0209 | 1.000 | -2.42 | -2.42 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 5.54 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.129 | 0.800 | -2.47 | -1.976 | [0.5 - 2] |
Total Score | 9.60 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 14.91 | 1.000 | 8.59 | 0 | [1 - 100] |
returnOnEquityTTM | 0.132 | 2.50 | 9.77 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.971 | 2.00 | -0.324 | -0.971 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.935 | 2.00 | 9.35 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 1.442 | 1.500 | 3.72 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.290 | 1.000 | 5.25 | 0 | [0.1 - 0.5] |
Total Score | 3.88 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं